Related Experiment Video
Updated: Oct 11, 2025

Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
Dimethyl Fumarate Alleviates NLRP3 Inflammasome Activation in Microglia and Sickness Behavior in LPS-Challenged Mice
Bora Tastan1,2, Burak I Arioz1,2, Kemal Ugur Tufekci1,3
1Genc Laboratory, Izmir Biomedicine and Genome Center, Izmir, Turkey.
Abstract:
NLRP3 inflammasome activation contributes to several pathogenic conditions, including lipopolysaccharide (LPS)-induced sickness behavior characterized by reduced mobility and depressive behaviors. Dimethyl fumarate (DMF) is an immunomodulatory and anti-oxidative molecule commonly used for the symptomatic treatment of multiple sclerosis and psoriasis. In this study, we investigated the potential use of DMF against microglial NLRP3 inflammasome activation both in vitro and in vivo. For in vitro studies, LPS- and ATP-stimulated N9 microglial cells were used to induce NLRP3 inflammasome activation. DMF's effects on inflammasome markers, pyroptotic cell death, ROS formation, and Nrf2/NF-κB pathways were assessed. For in vivo studies, 12-14 weeks-old male BALB/c mice were treated with LPS, DMF + LPS and ML385 + DMF + LPS. Behavioral tests including open field, forced swim test, and tail suspension test were carried out to see changes in lipopolysaccharide-induced sickness behavior. Furthermore, NLRP3 and Caspase-1 expression in isolated microglia were determined by immunostaining. Here we demonstrated that DMF ameliorated LPS and ATP-induced NLRP3 inflammasome activation by reducing IL-1β, IL-18, caspase-1, and NLRP3 levels, reactive oxygen species formation and damage, and inhibiting pyroptotic cell death in N9 murine microglia via Nrf2/NF-κB pathways. DMF also improved LPS-induced sickness behavior in male mice and decreased caspase-1/NLRP3 levels via Nrf2 activation. Additionally, we showed that DMF pretreatment decreased miR-146a and miR-155 both in vivo and in vitro. Our results proved the effectiveness of DMF on the amelioration of microglial NLRP3 inflammasome activation. We anticipate that this study will provide the foundation consideration for further studies aiming to suppress NLRP3 inflammasome activation associated with in many diseases and a better understanding of its underlying mechanisms.
Insights
Dimethyl fumarate (DMF) effectively reduces microglial NLRP3 inflammasome activation, a key factor in sickness behavior. This immunomodulatory compound ameliorates inflammation and improves behavior in LPS-induced models.
Area of Science:
- Neuroimmunology
- Inflammation research
- Pharmacology
Background:
- NLRP3 inflammasome activation is implicated in pathogenic conditions like lipopolysaccharide (LPS)-induced sickness behavior.
- Dimethyl fumarate (DMF) possesses immunomodulatory and anti-oxidative properties, with established therapeutic uses.
Purpose of the Study:
- To investigate the efficacy of DMF in mitigating microglial NLRP3 inflammasome activation both in vitro and in vivo.
- To elucidate the underlying mechanisms of DMF's action on inflammatory pathways and behavior.
Main Methods:
- In vitro studies utilized LPS- and ATP-stimulated N9 microglial cells to assess inflammasome markers, pyroptosis, ROS, and Nrf2/NF-κB pathways.
- In vivo studies involved LPS-challenged male mice treated with DMF, assessing behavioral changes and NLRP3/Caspase-1 expression in microglia.
- MicroRNA expression (miR-146a, miR-155) was also evaluated.
Main Results:
- DMF significantly reduced LPS/ATP-induced NLRP3 inflammasome activation markers (IL-1β, IL-18, caspase-1, NLRP3), ROS formation, and pyroptotic cell death in microglia.
- DMF treatment ameliorated LPS-induced sickness behavior in mice and decreased NLRP3/caspase-1 levels via Nrf2 activation.
- DMF pretreatment also led to a decrease in miR-146a and miR-155 expression.
Conclusions:
- DMF demonstrates significant potential in ameliorating microglial NLRP3 inflammasome activation and associated pathologies.
- The findings support DMF's therapeutic utility in diseases driven by NLRP3 inflammasome hyperactivity.
- This study provides mechanistic insights into DMF's anti-inflammatory effects via Nrf2 activation and modulation of specific microRNAs.

